Immunitybio Inc (IBRX)

Nov 9, 2026

ImmunityBio Inc. (NASDAQ: IBRX) stock declined on Monday after reporting third-quarter earnings that missed analyst expectations, with an adjusted loss of 9 cents per share and sales of $48.84 million, both below consensus estimates. The company's net loss widened significantly due to derivative adjustments and increased R&D and SG&A expenses. Despite the financial miss, ImmunityBio announced positive final results from its ANKTIVA bladder cancer trial and received accelerated approval for ANKTIVA in Israel.

Nov 9, 2026

ImmunityBio announced that its Anktiva plus BCG combination therapy met its primary endpoint in a Phase 2b trial for BCG-naïve bladder cancer patients, showing improved efficacy over BCG alone. The company, however, withheld specific response rates and detailed statistical data, although it confirmed no new safety concerns. ImmunityBio plans to submit a supplemental biologics license application to the FDA by year-end 2026 to expand Anktiva's indication for earlier treatment.

Nov 4, 2026

ImmunityBio (IBRX) announced that the first patients in Europe have received its bladder cancer treatment, Anktiva, combined with Bacillus Calmette-Guérin (BCG), following conditional approval from the European Commission in February 2026. Treatments began in Germany and Austria for patients with BCG-unresponsive non-muscle invasive bladder cancer. The company expects to report its third-quarter results soon, with Wall Street anticipating $59.2 million in revenue and a loss of $0.08 per share.